From $49 to $110: Why Piper Sandler Thinks CRSP Can More Than Double From Here

Piper Sandler raised its CRISPR Therapeutics (CRSP) price target to $110 (implying >120% upside) after a $600M convertible note (convertible at $76.56, 1.73% effective coupon) increased pro forma cash to $2.56B. Shares trade around $49.37 (down 5% over the past week, down 8% YTD), while CASGEVY generated $116M in 2025 revenue with patient starts nearly tripling year-over-year and a pediatric label filing expected H1 2026. The firm highlights pipeline catalysts — CTX310 moving to Phase 1b with NEJM-published data and multiple trials (CTX340, CTX460, zugo-cel, CTX611) funded by the extended cash runway — but notes execution risk given continued operating losses and the need for positive clinical/readout validation to reach the $110 target.

Analysis

The convertible financing alters market microstructure more than headline liquidity: holders will behave like option sellers and hedgers, which tends to cap short-term rallies while expanding implied volatility term structure. That dynamic creates a persistent premium for longer-dated calls and opens arbitrage windows for volatility and basis trades rather than pure directional exposure.

Manufacturing and payer pathways are the underappreciated battlegrounds. Scaling one-off cell/gene therapies tends to bottleneck at a small number of CDMOs and hospital infusion capacity, producing winners among specialized manufacturers and sequencing logistics providers while delaying revenue realization for the sponsor even after label wins. Separately, negotiated reimbursement timelines can stretch adoption curves by quarters; a regulatory approval alone will not guarantee rapid premium payer coverage.

Institutional concentration and a multi-program development strategy amplify binary risk: success in a non-core program can re-rate the platform rapidly, but a single negative readout or slower-than-expected commercial uptake could lead to outsized outflows given limited free float. This asymmetric payoff favors structured exposure that limits downside while preserving multi-hundred-percent upside on a small notional, and creates fertile ground for relative-value trades versus platform peers and supply-chain beneficiaries over the next 12–36 months.

Key Decisions for Investors

• Directional asymmetric: Buy long-dated call spread on CRSP (18–24 month expiry). Finance premium by selling a far OTM call to cap upside; target trade to capture multi-catalyst re-rate while limiting max loss to premium paid. Use position sizing so max portfolio drawdown if trade fails is <1%.
• Hedge pair: Long CRSP equity (smaller size) paired with short Intellia (NTLA) or Editas (EDIT) to isolate company-specific execution vs platform risk. Hold through 12–24 months; trim on first positive mid-stage readout or on >30% leg divergence. Expected asymmetric payoff: 2–3x upside on long leg vs 1:1 downside on short.
• Volatility calendar: Sell near-term implied vol (2–3 month) and buy longer-dated vol (9–18 month) via calendar spreads in CRSP options to monetize expected IV term-structure steepness after financing news. Vulnerable to near-term binary events (use tight stops).
• Supply-chain long: Add exposure to specialized CDMOs and logistics names (e.g., CTLT, TMO) on 12–36 month horizon to capture scaling demand irrespective of binary clinical outcomes. Risk: durable demand depends on multiple sponsors' commercial success; size as defensive exposure.